Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

pSivida enters tech evaluation deal with Neuron Systems

PSivida : 15 March, 2012  (Company News)
pSivida is entering into a technology evaluation agreement for its bioerodible Durasert drug delivery technology in ophthalmology with Neuron Systems, an ocular drug development company based in Burlington, Massachusetts, USA.
Under the agreement, the companies will evaluate the use of pSivida's technology as a delivery system for a treatment for dry age related macular degeneration (Dry AMD), a serious retinal disease that afflicts millions of patients worldwide and can lead to blindness.

"While Wet AMD, which affects less than 20 percent of the population with AMD, is well treated with products such as Genentech's billion dollar Lucentis and/or Regeneron's Eylea, there currently is no approved treatment for Dry AMD, a disease which affects far more people," said Dr Paul Ashton, President and Chief Executive Officer of pSivida. Dr Ashton added: "This is the second tech evaluation agreement pSivida has signed for its bioerodible Durasert technology since pSivida regained the rights to its intellectual property from Pfizer last year."

"We are very pleased to enter into this technology evaluation agreement with pSivida as we believe the combination of Durasert and our proprietary compounds may provide an exciting new approach to treating this devastating disease," commented Dr Todd Brady, Chief Executive Officer of Neuron Systems.

pSivida is also independently developing a product to treat uveitis affecting the posterior segment of the eye (posterior uveitis) and a product to treat glaucoma and ocular hypertension in collaboration with Pfizer.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo